Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes.

Nwose OM, Jones MR.

Clin Med Insights Endocrinol Diabetes. 2013 Dec 8;6:75-9. doi: 10.4137/CMED.S12590. Review.

2.

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.

Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK.

Diabetologia. 2012 Feb;55(2):432-42. doi: 10.1007/s00125-011-2382-3. Epub 2011 Dec 2.

PMID:
22134839
3.

Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.

Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, Kliewer SA, Burgess SC.

Am J Physiol Gastrointest Liver Physiol. 2013 Feb 15;304(4):G371-80. doi: 10.1152/ajpgi.00400.2012. Epub 2012 Dec 20.

4.

Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.

Holst JJ, McGill MA.

Clin Drug Investig. 2012 Jan 1;32(1):1-14. doi: 10.2165/11595370-000000000-00000. Review.

PMID:
21958333
5.

Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.

Rosenstock J, Truitt KE, Baz-Hecht M, Ford DM, Tao B, Chou HS.

Horm Metab Res. 2014 Dec;46(13):943-9. doi: 10.1055/s-0034-1383648. Epub 2014 Jul 23.

PMID:
25054436
6.

Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.

Hansen M, Scheltema MJ, Sonne DP, Hansen JS, Sperling M, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK.

Diabetes Obes Metab. 2016 Jun;18(6):571-80. doi: 10.1111/dom.12648. Epub 2016 Mar 22.

PMID:
26888164
7.

Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus.

Sonnett TE, Levien TL, Neumiller JJ, Gates BJ, Setter SM.

Clin Ther. 2009 Feb;31(2):245-59. doi: 10.1016/j.clinthera.2009.02.018. Review.

PMID:
19302898
9.

Advances in the treatment of type 2 diabetes mellitus.

Israili ZH.

Am J Ther. 2011 Mar-Apr;18(2):117-52. doi: 10.1097/MJT.0b013e3181afbf51. Review.

PMID:
19834322
10.

More choices than ever before: emerging therapies for type 2 diabetes.

Campbell RK, White JR Jr.

Diabetes Educ. 2008 May-Jun;34(3):518-34. doi: 10.1177/0145721708317870.

PMID:
18535325
11.
12.

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Abbatecola AM, Maggi S, Paolisso G.

Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002. Review.

PMID:
18947259
13.
14.

The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.

Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C, Zinsmeister AR, Rizza RA, Vella A.

Diabetes. 2013 Apr;62(4):1094-101. doi: 10.2337/db12-0923. Epub 2012 Dec 18.

15.
16.
17.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
18.

Complementing insulin therapy to achieve glycemic control.

Barnett AH.

Adv Ther. 2013 Jun;30(6):557-76. Review.

PMID:
23797471
19.

Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Zarrinpar A, Loomba R.

Aliment Pharmacol Ther. 2012 Nov;36(10):909-21. doi: 10.1111/apt.12084. Epub 2012 Oct 11. Review.

20.

The entero-insular axis: implications for human metabolism.

Ranganath LR.

Clin Chem Lab Med. 2008;46(1):43-56. Review.

PMID:
18020966

Supplemental Content

Support Center